glp-1 gip therapies muscle preservation 2025 Weight loss with medicines does not result in a disproportionate loss of mass or function in obese mice and humans: Cell Reports Medicine Optimizing GLP-1 therapies for obesity
Description
10.2337/db05-1602 [DOI] [PubMed] [Google Scholar] 136.Takeda Y, Fujita Y, Honjo J, Yanagimachi T, Sakagami H, Takiyama Y, et al
QRISK3-based analysis of cardiovascular risk factors in patients with long-term but well-controlled systemic lupus erythematosus
Glucagon-like peptide-1 receptor agonists and prevention of stroke
Conclusion The perioperative management of patients receiving GLP-1 receptor agonists and dual incretin agonists has undergone marked evolution as understanding of these therapies has expanded
[25] Mineur YS, Abizaid A, Rao Y, et al
Too quickly, perhaps
